SG&A Efficiency Analysis: Comparing Viatris Inc. and TG Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and TG Therapeutics, Inc. over the past decade. Viatris, a global healthcare giant, consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, TG Therapeutics, a smaller biotech firm, showed a more modest increase, with expenses reaching around $123 million in the same year.

Key Insights

From 2014 to 2023, Viatris's SG&A expenses grew by over 200%, reflecting its expansive operations. Meanwhile, TG Therapeutics saw a nearly 400% increase, indicating aggressive growth strategies. This stark contrast highlights the differing scales and strategies of these companies. Investors and analysts can glean insights into each company's operational focus and market positioning from these trends.